Sanofi’s second chance: Why Europe is warming up to Rezurock after initial CHMP rejection

Sanofi SA’s Rezurock (belumosudil) has received a conditional approval recommendation from the Committee for Medicinal Products for Human Use of the European Medicines Agency for the treatment of chronic graft-versus-host disease. The shift follows a regulatory U-turn after the same committee issued a negative opinion in October 2025. With this new decision, the chronic post-transplant condition may finally receive a treatment specifically designed for patients with limited or no response to corticosteroids and other systemic therapies.

Chronic graft-versus-host disease is a severe immune complication that can affect multiple organs following allogeneic stem cell transplantation. While corticosteroids remain the standard first-line option, many patients experience limited efficacy or intolerable toxicity, leaving them without durable solutions. The CHMP’s new stance on Rezurock directly addresses this therapeutic void. It confirms that the European Commission is likely to grant conditional marketing authorisation for the drug in adults and adolescents aged 12 and over when no suitable alternatives are available. This development not only opens up access for a previously underserved patient population but also reaffirms the role of targeted small molecule immunomodulators in difficult-to-treat inflammatory conditions.

The recommendation was based on a combination of clinical and real-world evidence, primarily from the phase 2 ROCKstar study. The trial demonstrated that Rezurock, a selective ROCK2 inhibitor, could deliver meaningful and sustained clinical responses in patients who had failed multiple prior therapies. These results were complemented by real-world outcomes data that reinforced its potential utility in clinical practice. Importantly, the recommendation comes with the expectation that Sanofi SA will generate further confirmatory evidence through ongoing post-marketing studies, a typical condition of the European Union’s early-access approval pathway.

The shift from a previous rejection to a positive recommendation reflects both the responsiveness of European regulators and Sanofi SA’s persistence in refining its regulatory submission. The CHMP’s earlier rejection raised concerns about the robustness of efficacy data and comparative effectiveness. Sanofi SA’s re-examination request appears to have satisfied those concerns, possibly through additional analyses or data from real-world registries that contextualized the clinical benefit in a patient population with no good options.

For transplant physicians and haematologists, the drug’s conditional approval could help fill a longstanding treatment gap. Sanofi SA’s strategy to re-engage with regulators after the initial setback demonstrates not only persistence but also adaptability in navigating the complex regulatory landscape of rare disease therapies. The revised CHMP opinion validates this approach, offering a template for other drugmakers seeking approval in high-need, low-alternative segments of the rare disease spectrum.

How does the EU recommendation reshape Sanofi’s rare disease portfolio and competitive landscape in transplant immunology?

Rezurock’s conditional recommendation by European regulators represents more than a product milestone. It is a strategic expansion of Sanofi SA’s immunology and rare disease portfolio into an underdeveloped niche. The company has established therapeutic positions in multiple rare and specialty disease areas, but until now, its presence in transplant-related immunology has remained limited. Rezurock’s entry into the European market could open access to a high-need, low-competition segment with long-term growth potential.

Currently, very few therapies are specifically approved for chronic graft-versus-host disease beyond corticosteroids and general immunosuppressants. Rezurock’s selective mechanism of action, targeting the ROCK2 pathway implicated in tissue fibrosis and inflammation, distinguishes it from the broader class of nonspecific immune modulators. That scientific differentiation could appeal to clinicians seeking new mechanistic approaches for steroid-refractory or steroid-intolerant patients.

Globally, Rezurock is already authorised in more than 20 markets, including the United States, United Kingdom, Canada, and China. The European Union market is the next major milestone. If approved, it would solidify Sanofi SA’s footprint in advanced immunology while enabling geographic portfolio harmonisation. It would also signal regulatory convergence across major markets on the clinical validity of the ROCK2 pathway in chronic inflammatory and fibrotic disorders.

Commercially, however, challenges remain. Even with conditional approval, Sanofi SA must negotiate reimbursement agreements across individual EU member states, each with their own health technology assessment frameworks. Payer bodies in France, Germany, Italy, Spain, and other large markets will likely scrutinise not only the drug’s efficacy and safety but also its cost-effectiveness relative to current standards of care. For a rare disease therapy, this pricing debate could affect both launch speed and uptake trajectory.

Moreover, Sanofi SA will be required to execute a confirmatory study post-approval to retain its conditional authorisation. The outcome of this study will be critical for securing long-term label expansion and possibly transitioning from conditional to full approval status. Delays or underwhelming results in that trial could limit physician confidence or trigger reimbursement review cycles.

From a competitive standpoint, the landscape is relatively open but not entirely uncontested. Other agents, including ruxolitinib and ibrutinib, are used off-label in various transplant-related immune complications. However, their use in chronic graft-versus-host disease remains limited by inconsistent evidence and side effect profiles. Rezurock’s label, if approved, will be one of the few specifically tailored to cGVHD, positioning it as a go-to option for late-line management in eligible patients.

What are the next steps after CHMP approval and how might investor sentiment evolve around Sanofi’s Rezurock strategy?

The conditional recommendation sets the stage for the European Commission to grant formal marketing authorisation in the coming weeks. Once approved, Sanofi SA will begin country-level launch planning, focusing on market access and education among transplant specialists. Timelines for commercial availability will depend on how quickly the company can secure favourable pricing and reimbursement terms across EU jurisdictions.

From a clinical adoption perspective, Rezurock will likely be positioned for patients with prior therapy failure or intolerance, making it an option for a relatively narrow but clinically urgent patient pool. Its real-world performance in these scenarios will be closely monitored, not only by physicians but also by regulators and payers seeking justification for continued access.

Investor sentiment following the CHMP decision has been cautiously optimistic. Sanofi SA, which trades under the SNY ticker in both Paris and through American depositary receipts, saw modest positive movement in pre-market trading following the announcement. Analysts tracking the company’s pipeline have pointed to Rezurock as a case study in regulatory turnaround. The successful reversal of a negative opinion enhances investor perception of Sanofi SA’s regulatory and medical affairs execution strength, particularly in rare and specialty diseases where trial design and patient selection can be complex.

Financially, while Rezurock may not immediately contribute significantly to topline revenue, it could offer high-margin upside over time. Orphan drug pricing strategies, combined with minimal competition and a defined patient base, typically support premium positioning. If Sanofi SA is able to expand the indication in future or apply similar pathways in other rare autoimmune or fibrotic disorders, the ROCK2 platform may have broader pipeline implications.

Ultimately, the company’s ability to convert conditional approval into long-term market presence will hinge on the success of its confirmatory program, pricing strategy, and engagement with clinical stakeholders. Regulatory wins matter, but sustained execution will determine whether Rezurock becomes a cornerstone in Sanofi SA’s rare disease portfolio or a footnote in a competitive and cost-conscious European market.

What are the key takeaways for Sanofi, its competitors, and the chronic GVHD treatment landscape in Europe?

• Sanofi SA’s Rezurock secured a conditional approval recommendation from the CHMP for chronic graft-versus-host disease, reversing a prior rejection.

• The recommendation reflects clinical trial and real-world evidence showing durable responses in patients with few or no other treatment options.

• Rezurock targets the ROCK2 pathway and offers a mechanistically distinct option in a field dominated by corticosteroids and broad immunosuppressants.

• The positive CHMP opinion sets the stage for European Commission approval and subsequent market access work across EU member states.

• Sanofi SA will be required to conduct confirmatory post-marketing studies to retain conditional approval and advance toward full authorisation.

• Investor sentiment has been modestly positive, signalling confidence in regulatory execution and incremental revenue potential from orphan drug strategies.

• Rezurock, if approved, will join a small group of drugs with specific indications for chronic graft-versus-host disease, offering clinical differentiation.

• Execution risks remain, particularly around reimbursement, pricing negotiations, and uptake in a fragmented European healthcare landscape.

• The decision signals EMA’s willingness to reconsider previous verdicts in the context of unmet need and evolving data quality in rare diseases.

• For competitors, the approval marks a renewed focus on transplant-related complications as viable therapeutic and commercial targets.